文献速递关节外科

非甾体抗炎药与口服糖皮质激素降低全膝关节置换术后关节纤维化风险

Nonsteroidal Anti-Inflammatory Drugs and Oral Corticosteroids Mitigated the Risk of Arthrofibrosis After Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2023-04-01

基于总关节登记系统纳入2000至2016年9771例(12735膝)初次全膝关节置换患者,454膝(4%)诊断关节纤维化并与对照1:2匹配。围手术期非甾体抗炎药使用与关节纤维化风险降低相关(OR 0.67,P=0.045),口服糖皮质激素与手法松解风险降低相关(OR 0.26,P=0.036)。

要点

  • 围手术期使用非甾体抗炎药与关节纤维化风险降低相关(OR 0.67,P=0.045)。
  • 围手术期口服糖皮质激素与手法松解风险降低相关(OR 0.26,P=0.036)。
  • 糖皮质激素与关节纤维化风险(OR 0.52,P=0.098)及非甾体抗炎药与手法松解风险(OR 0.69,P=0.11)仅呈趋势。

核心结论

  • 围手术期使用非甾体抗炎药与关节纤维化风险降低相关,并呈降低后续手法松解风险的趋势。
  • 口服糖皮质激素与手法松解风险降低相关,并呈降低关节纤维化风险的趋势。

研究设计与样本

  • 利用总关节登记系统识别2000年至2016年接受骨水泥固定、后稳定型、金属背衬胫骨组件全膝关节置换的9771例患者(12735膝)。
  • 关节纤维化定义为术后活动度≤90°持续≥12周或活动度≤90°需手法松解,诊断454膝(4%),按1:2匹配对照。
  • 平均年龄62岁(范围19至87),57%为女性,多数手术诊断为骨关节炎,平均随访8年(范围2至20)。
  • 围手术期使用他汀类、血管紧张素转换酶抑制剂、血管紧张素II受体阻滞剂、口服糖皮质激素、抗组胺药和非甾体抗炎药经人工确认,采用校正多变量分析评估药物效果。

主要发现

  • 围手术期使用非甾体抗炎药与关节纤维化风险降低相关(OR 0.67,P=0.045)。
  • 围手术期使用糖皮质激素与关节纤维化风险降低呈趋势(OR 0.52,P=0.098)。
  • 糖皮质激素与手法松解风险降低相关(OR 0.26,P=0.036)。
  • 非甾体抗炎药与手法松解风险降低呈趋势(OR 0.69,P=0.11)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of medications to prevent arthrofibrosis following total knee arthroplasty (TKA) remains unclear. We investigated the effect of common oral medications with reported antifibrotic properties on preventing arthrofibrosis and manipulation under anesthesia (MUA) following primary TKA. METHODS: Using our total joint registry, 9,771 patients (12,735 knees) who underwent TKA with cemented, posterior-stabilized, and metal-backed tibial components from 2000 to 2016 were identified. Arthrofibrosis, defined as range of motion (ROM) ≤90° for ≥12 weeks postoperatively or as ROM ≤90° requiring MUA, was diagnosed in 454 knees (4%) and matched 1:2 to controls. Mean age was 62 years (range, 19 to 87) and 57% were women. The majority of operative diagnoses were osteoarthritis. Perioperative use of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins), angiotensin converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), oral corticosteroids, antihistamines, and nonsteroidal anti-inflammatory drugs (NSAIDs) were manually confirmed. Medication effect in preventing arthrofibrosis and MUA was assessed using adjusted multivariable analyses. Mean follow-up was 8 years (range, 2 to 20). RESULTS: Reduced risk of arthrofibrosis was associated with perioperative NSAID use (odds ratio (OR) 0.67, P = .045). A similar trend was observed with perioperative corticosteroids (OR 0.52, P = .098). Corticosteroids were associated with reduced risk of MUA (OR 0.26, P = .036), and NSAIDs trended towards reducing MUA (OR 0.69, P = .11). CONCLUSION: This investigation determined that perioperative NSAID use was associated with reduced risk of arthrofibrosis and trended towards reduced risk of subsequent MUA. Similarly, oral corticosteroids were associated with reduced risk of MUA and trended towards reduced risk of arthrofibrosis.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Salmons HI, Payne AN, Taunton MJ, et al. Nonsteroidal Anti-Inflammatory Drugs and Oral Corticosteroids Mitigated the Risk of Arthrofibrosis After Total Knee Arthroplasty. J Arthroplasty. 2023. PMID: 37011702. doi:10.1016/j.arth.2023.03.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。